SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2870)3/26/2020 6:22:19 PM
From: Biotechwantabe  Read Replies (2) | Respond to of 3557
 
Note that vir is partnering with alny
Going by the agreement, the companies will leverage Alnylam’s recent advances in lung delivery of novel conjugates of siRNA along with Vir’s expertise in infectious disease and established capabilities to develop one or more siRNAs to treat SARS-CoV-2 and potentially other coronaviruses as well. siRNA is the molecule that mediates RNAi.
investors.alnylam.com



To: Miljenko Zuanic who wrote (2870)3/27/2020 12:57:24 AM
From: CuttingEdge Bio  Read Replies (1) | Respond to of 3557
 
Well I credit them for trying, but they are rather "new" and so I'm unfamiliar with them. Would be hard to believe they can move quickly enough, or that they bring any special skill to the table. But more shots on goal against covid the better is my feeling on it.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News